Senior insider sale
CHIEF SCIENTIFIC OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$4.15M
130K shares
What this filing means
LYSSIKATOS JOSEPH P plans to sell 130K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $4.15M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 4/30/2026ACC: 0001974158-26-000062
Officer· CHIEF SCIENTIFIC OFFICER
Since Feb 2026
130K
Shares to sell
$4.15M
Approx. market value
25K
Acquired (3 months)
1
Planned
5 completed
Securities Acquired — Last 3 Months1
Founder shares
N/A
9/1/2019
25KTotal acquired25K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
9/1/2019 | Founder shares N/A | 25K | — |
| Total | 25K | ||
Planned & Completed Dispositions6
Completed
—Completed
Units to sell
25K
Market value
$965.8K
3/31/2026
—Completed
Units to sell
5K
Market value
$144.6K
2/25/2026
—Completed
Units to sell
20K
Market value
$520.2K
2/19/2026
—Completed
Units to sell
50K
Market value
$1.32M
2/18/2026
—Completed
Units to sell
5K
Market value
$145.2K
2/6/2026
Planned — Approximate Date
NasdaqPlanned
Units to sell
25K
Market value
$1.06M
4/30/2026
Total
Units
130K
Value
$4.15M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
3/31/2026 | 25K | $965.8K | — | Completed |
2/25/2026 | 5K | $144.6K | — | Completed |
2/19/2026 | 20K | $520.2K | — | Completed |
2/18/2026 | 50K | $1.32M | — | Completed |
2/6/2026 | 5K | $145.2K | — | Completed |
| Planned — Approximate Date | ||||
4/30/2026 | 25K | $1.06M | Nasdaq | Planned |
| Total | 130K | $4.15M | ||